Chimerix to Present at Virtual H.C. Wainwright Global Life Sciences Conference

Rhea-AI Summary

DURHAM, N.C., March 2, 2021 - Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 a.m. ET. The presentation will be available via an audio webcast on the Investor Relations section of Chimerix's website, archived for 90 days.

Chimerix focuses on developing medicines for cancer and severe diseases, with leading programs including BCV, ONC201, and DSTAT, aiming for regulatory approval for BCV as a smallpox treatment.

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright Global Life Sciences Conference made available on Tuesday, March 9, 2021 at 7:00 a.m. ET.

An audio webcast of the presentation will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. Our three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include those relating to, among other things, Chimerix’s ability to obtain regulatory approval for BCV; the timing and receipt of a potential procurement contract for BCV in smallpox; and the timing of enrollment in the DSTAT trial for AML. Among the factors and risks that could cause actual results to differ materially from those indicated in the forward-looking statements are risks that BCV may not obtain regulatory approval from the FDA or such approval may be delayed or conditioned; risks that Chimerix will not obtain a procurement contract for BCV in smallpox in a timely manner or at all; risks related to the timing and conduct of the DSTAT trials for AML and COVID; risks that ongoing or future trials may not be successful or replicate previous trial results, or may not be predictive of real-world results or of results in subsequent trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for our drugs; risks that our drugs may be precluded from commercialization by the proprietary rights of third parties; and additional risks set forth in the Company's filings with the Securities and Exchange Commission. These forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.

CONTACT:
Investor Relations:        
Michelle LaSpaluto
919 972-7115
ir@chimerix.com

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

FAQ

When will Chimerix's CEO present at the H.C. Wainwright Conference?

Mike Sherman, CEO of Chimerix, will present on March 9, 2021, at 7:00 a.m. ET.

How can I access Chimerix's presentation from the conference?

The presentation will be available as an audio webcast on Chimerix's Investor Relations website, archived for 90 days.

What are the primary drug candidates for Chimerix?

Chimerix's leading clinical-stage programs include BCV, ONC201, and DSTAT.

What is the status of BCV for Chimerix?

BCV is under review for regulatory approval in the United States as a potential smallpox treatment.

What is the purpose of ONC201 in Chimerix's development pipeline?

ONC201 is in a registrational clinical program for recurrent H3 K27M-mutant glioma.

Is DSTAT being developed for COVID-19 patients?

Yes, DSTAT is in development as a potential treatment for acute lung injury in hospitalized COVID-19 patients.